Natco Pharma Q1 2021-22 Investor Presentation

Natco Pharma is a vertically integrated pharmaceutical company with consolidated revenues of INR 21.6 billion for FY2021, operating across India, US, and international markets. The company maintains a strong domestic brand position in oncology, cardiology, and diabetes, while focusing on complex generics for US markets and expansion into agrichemicals. Listed on BSE and NSE with ~5,000 employees, Natco combines two R&D centers and over 525 research staff to drive growth across its pharmaceutical portfolio.